This implies that interference with the innate immune system with medicinal drugs, such as the IgLC-binding peptide modeled here, should be effective equally conditionally when other targets are chosen, such as TNF (an effective target in the treatment of rheumatoid arthritis (49, 70) or one of the MMPs. The gene discussed is TNF; the disease is rheumatoid arthritis.